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he human brain has remained
largely uncharted, but a detailed
new map by Washington
University researchers lays out the
landscape of the cerebral cortex — the
dominant structure involved in sensory
perception, attention, language, tool use
and abstract thinking.
The map divides both the left and right
cerebral hemispheres into 180 areas based
on physical differences, functional distinctions
and variations in the connections.
The researchers drew upon data and
methods generated by the Human
Connectome Project (HCP), a five-year,
multimillion dollar study led by David Van
Essen, PhD, the Alumni Endowed Professor
of Neuroscience, and involving a consortium
that includes the University of Minnesota
and Oxford University. The HCP used a
powerful, custom-built MRI machine to
map the brains of 1,200 young adults.
To make this new map, the study’s lead
author Matthew Glasser, PhD, Van Essen
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and colleagues pooled data from 210
healthy young adults. The researchers
combined measures of the thickness of
the cortex and the amount of insulation
around neuronal cables, with MRI scans
of the brain at rest and while performing
simple tasks, such as listening to a story.
“We ended up with 180 areas in each
hemisphere, but we don’t expect that to be
the final number,” Glasser said. “In some
cases, we identified a patch of cortex that
probably could be subdivided, but we
couldn’t confidently draw borders with our
current data and techniques. In the future,
researchers with better methods will
subdivide that area. We focused on borders
we are confident will stand the test of time.”
The researchers improved on previous
maps by aligning the brains to a common

The map divides both
the left and right cerebral
hemispheres into 180 areas.
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Map provides detailed picture
of how the brain is organized
David Van Essen, PhD (left), and Matthew Glasser,
PhD, are part of a team that mapped the human
cerebral cortex in painstaking detail. The map will
help researchers study brain disorders such as autism,
schizophrenia, dementia and epilepsy.
coordinate system before analysis, using
an algorithm developed by colleagues at
Oxford University, and incorporating the
highest-quality MRI data available.
The results are a precise map with
crisp borders and an algorithm capable of
locating the areas in individual brains, even
though each individual is unique in terms
of the pattern of cortical folds and in the
size and shape of areas on the cortical map.
The work is available online in Nature,
including 200 pages of detailed information
on each of the 180 regions and algorithms
used. “We think it will serve the scientific
community best if they can dive down
and get these maps onto their computer
screens and explore as they see fit,”
Van Essen said.
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Signaling a potential new approach to treating diabetes,
researchers at the School of Medicine and Harvard
University have produced insulin-secreting cells from
stem cells derived from patients with type 1 diabetes.
The discovery suggests a personalized treatment approach
may be on the horizon — one that relies on the patients’ own
stem cells to manufacture new cells that make insulin.
The researchers showed that the new cells could produce
insulin when they encountered sugar. The scientists tested
the cells in culture and in mice, and in both cases found
that the cells secreted insulin in response to glucose.
“In theory, if we could replace the damaged cells in
these individuals with new pancreatic beta cells — whose
primary function is to store and release insulin to control
blood glucose — patients
with type 1 diabetes
wouldn’t need insulin
shots anymore,” said
first author Jeffrey
R. Millman, PhD, an
assistant professor
of medicine and
of biomedical
engineering at the
School of Medicine.
Millman, whose
laboratory is in
Jeffrey R. Millman, PhD
the Division of
Endocrinology, Metabolism and Lipid Research, began
his research in the laboratory of Douglas A. Melton,
PhD, Howard Hughes Medical Institute investigator and
a co-director of Harvard’s Stem Cell Institute. There,
Millman had used similar techniques to make beta cells
from stem cells derived from people who did not have
diabetes. In these new experiments, the beta cells came
from tissue taken from the skin of diabetes patients.
More research is needed to make sure that the beta cells
made from patient-derived stem cells don’t cause tumors to
develop — a problem that has surfaced in some stem cell
research — but there has been no evidence of tumors in the
mouse studies, even up to a year after the cells were implanted.
Stem cell-derived beta cells could be ready for human
research in three to five years. At that time, Millman expects
the cells would be implanted under the skin of diabetes
patients in a minimally invasive surgical procedure that
would allow the beta cells access to a patient’s blood supply.
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Insulin-secreting cells
created from stem cells
DEVELOPMENTAL STUDY Preemies whose daily
diets were at least 50 percent breast milk had more brain tissue
and cortical surface area by their due dates than premature
babies who consumed significantly less breast milk. Led by
Cynthia Rogers, MD, assistant professor of child psychiatry, the
researchers retrospectively studied how much breast milk 77
preterm babies received while in the Neonatal Intensive Care
Unit (NICU) at St. Louis Children’s Hospital, then conducted
brain scans at about the time of their full-term due dates.

New Institute for Informatics
to coordinate big data efforts
From analyzing vast DNA sequences to handling electronic
medical records, the importance of big data in medicine has
increased dramatically in recent years. To support the need to
manage and harness big data, the medical school has launched
an Institute for Informatics, naming
Philip R.O. Payne, PhD, as director.
The school has a long history of
strong informatics research, which has
allowed Washington University to take
important leadership roles in national
bioinformatics efforts, including the
Human Genome Project, the Human
Connectome Project and the very recent
efforts to understand the microbiome.
Philip R.O. Payne, PhD
The institute will coordinate informatics efforts across the Medical Campus and partner with
the School of Engineering and Applied Science, the Institute
for Public Health, the Brown School, the Olin Business
School, the Innovations Incubator at BJC HealthCare and
the Cortex Innovation Community.
Payne, formerly chair of the Department of Biomedical
Informatics at The Ohio State University, is an elected fellow
of the American College of Medical Informatics. He has
written more than 175 peer-reviewed articles, book chapters,
abstracts, editorials and technical reports in his field.
Outlook 3
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STUDENT PLEDGE During orientation, the 124
incoming students collectively wrote a class oath representing
their ethics, values and goals. The oath-building tradition
began more than a decade ago and, with each class, a
different focus emerges. This year, students emphasized the
individual patient relationship. The class recited its oath at
the White Coat Ceremony, a rite of passage in which new
students receive their coats in front of family and friends.

I pledge that my patient will always be my
foremost consideration as I strive to promote
health and quality of life through education,
prevention and care.
See the full oath at wumcnews.org/2016oath

4 Washington University School of Medicine

A person’s genetic makeup plays a role in autoimmune
diseases that develop when the body is attacked by its
own immune system. But little is known about how
genetic variations push immune cells into overdrive.
Now, School of Medicine researchers have identified
genetic master switches that turn up — or down — the
activity of specific types of immune cells. The study is
available online in Cell.
Surprisingly, the DNA regions that make up these
master switches include numerous genetic variants
linked to a range of autoimmune diseases.
“In some cases,
individual variations
in a person’s DNA
probably tweak the
settings of these
switches upward,
leading to overactivation of the
immune cells and
autoimmune disease,”
said Eugene Oltz,
Super-enhancers found in DNA
PhD, a professor of
pathology and immunology and study co-senior author.
The researchers compared gene activity in two kinds
of immune cells — innate lymphoid cells and T helper
cells — that both serve as “control towers” for the immune
response, sending out powerful molecular signals to other
immune cells to start killing invading microbes and
destroying infected human cells.
The researchers defined a set of super-enhancers — regions
of DNA that serve as master control switches — for these
immune cell types. The super-enhancers contain many
genetic variants associated with autoimmune diseases
such as diabetes, rheumatoid arthritis, Crohn’s disease
and ulcerative colitis.
“Geneticists have identified lots of DNA sequence
variations associated with autoimmune diseases, but it
wasn’t clear how they were involved because they weren’t in
any genes known to be involved in the development of these
diseases,” said co-senior author Marco Colonna, MD, the
Robert Rock Belliveau, MD, Professor of Pathology. “Now
that we know where the master switches are, we can see
that those variants are associated with autoimmune disease
because they affect the regulation of these immune cells.”
The discovery could lead to personalized therapies targeted
to the genes regulated by each specific super-enhancer.
Autumn 2016
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Master switches turn up
immune cell activity

The Next Century
A Becker Medical Library
Photovoice Project

KATIE TAYLOR

CAITLIN CRANE, MLIS
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Share your (photo)voice: For more than 100 years,
the people of Washington University School of
Medicine and Barnes-Jewish and St. Louis Children’s
hospitals have worked together to advance
medicine, educate the next generation, and care
for patients in St. Louis and beyond. To celebrate
a century of collaboration, Bernard Becker Medical
Library has launched an online collection of
inspirational stories and photos. Those with
ties to Washington University Medical Center are
invited to take part at photovoice.wustl.edu.

Alzheimer’s decline linked to tau protein
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A

buildup of plaque and
dysfunctional proteins in the
brain are hallmarks of Alzheimer’s
disease. While much Alzheimer’s research
has focused on accumulation of the protein
amyloid beta, researchers have begun to pay
closer attention to another protein, tau, long
associated with this disease but not studied
as thoroughly, in part, because scientists only
recently have developed effective ways to
image tau.
Using a new imaging agent that binds to
tau protein and makes it visible in positron
emission tomography (PET) scans, School of
Medicine scientists have shown that measures
of tau are better markers of the cognitive
decline characteristic of Alzheimer’s than
measures of amyloid beta seen in PET scans.
A study comparing 36 control
participants who were cognitively normal
and 10 patients with mild Alzheimer’s
disease was published May 11 in the
journal Science Translational Medicine.
“Our work and that of others has shown
that elevated levels of amyloid beta are the
earliest markers of developing Alzheimer’s
disease,” said senior author Beau M. Ances,
MD, PhD, an associate professor of neurology.
“But in the earliest stages of Alzheimer’s
disease, even with amyloid buildup, many

patients are cognitively normal, meaning their
memory and thought processes are still intact.
What we suspect is that amyloid changes first
and then tau, and it’s the combination of both
that tips the patient from being asymptomatic
to showing mild cognitive impairment.”
While Ances called for larger follow-up
studies, he said this analysis helped establish
that the new tau agent, called T807, is an
important tool for understanding the timeline
of Alzheimer’s progression and for defining
which regions of the brain are involved. These
findings could lead to earlier diagnoses and

PET scans show average tau accumulation in
cognitively normal people (left) and in those with
mild Alzheimer’s symptoms.

clinical trials to test drugs against amyloid
and tau buildup.
“While we currently cannot prevent or
cure Alzheimer’s disease, delaying the onset
of symptoms by 10-15 years would make
a huge difference to our patients, to their
families and caregivers, and to the global
economy,” Ances said.
Outlook 5

USE SPARINGLY Prolonged use of drugs to treat
heartburn, ulcers and acid reflux may lead to serious
kidney damage, including kidney failure, according to
a large five-year study at the School of Medicine and
Veterans Affairs St. Louis Health Care System. More than
15 million Americans have prescriptions for so-called
proton pump inhibitors (PPIs), which generally have been
considered safe. The medications are sold under brand
names Prevacid, Prilosec, Nexium and Protonix, among
others. The epidemiological study is online in the Journal
of the American Society of Nephrology. The researchers
called for further study about the safety of PPIs.

National Academy members elected

Kenneth M. Murphy,
MD, PhD

Herbert W. “Skip”
Virgin IV, MD, PhD

Two scientists at the School of
Medicine are among the 84 members
and 21 foreign associates elected to
the National Academy of Sciences
this year. Election to the academy —
which was announced May 3 — is
considered one of the highest honors
that can be awarded to a U.S. scientist
or engineer.
The university’s newest academy
members are: Kenneth M. Murphy,
MD, PhD, the Eugene Opie Centennial
Professor of Pathology and Immunology
and a Howard Hughes Medical
Institute investigator; and Herbert
W. “Skip” Virgin IV, MD, PhD, the
Enjoy interactive elements and added
Edward Mallinckrodt Professor and
content of Pathology
head of the Department
and Immunology.
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Commonly touted as “good cholesterol” for helping to
reduce risk of stroke and heart attack, both high and low
levels of high-density lipoprotein (HDL) cholesterol may
increase a person’s risk of premature death, according
to new research at the School of Medicine and Veterans
Affairs (VA) St. Louis Health Care System.
Conversely, intermediate HDL cholesterol levels may
increase longevity, according to the research. The largescale epidemiological study is published in the Clinical
Journal of the American
Society of Nephrology.
“The findings surprised
us,” said Ziyad Al-Aly,
MD, an assistant professor
of medicine and the
study’s senior author.
“The relationship between
increased levels of HDL
cholesterol and early
death is unexpected and
not fully clear yet. This will require further study.”
For years, HDL cholesterol has been credited with helping
to remove plaque-building “bad cholesterol” from arteries.
For this study, researchers studied kidney function
and HDL cholesterol levels in more than 1.7 million male
veterans from October 2003 through September 2004, and
then followed participants until September 2013.
The study showed that both high and low HDL
cholesterol levels were associated with an increased risk of
dying among study participants with all levels of kidney
function. Research data showed a relationship between HDL
cholesterol levels and mortality as a U-shaped curve with
the risk of death increased at both ends of the spectrum.
“The findings may explain why clinical trials aimed at
increasing HDL cholesterol levels failed to show improved
outcomes,” said Al-Aly, who also is the VA’s associate chief
of staff for research and education and co-director of its
Clinical Epidemiology Center in St. Louis.
Such findings regarding HDL cholesterol and premature
death have not been reported in other large epidemiologic
studies, Al-Aly said.
“However, the previous studies are limited in that the
number of patients in those cohorts is relatively small
compared with what a big data approach enabled us to
see in our new research,” he said. “Big data allow a more
nuanced examination of the relationship between HDL
cholesterol and risk of death across the full spectrum of
HDL cholesterol levels.”
Autumn 2016
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‘Good cholesterol’ may
cause premature death
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Overcoming
disparities

M

From left to right: Mary Danielson, Tiffany Quan, Tiffany Son, Ailis Powderly, Laura J. Bierut,
MD, Foluso Ademuyiwa, MD, Tricia Salyer, Laura Muller and Karien Dixon.

edical and undergraduate
students are recruiting AfricanAmerican breast cancer patients for
a research project on genetic risks.
Historically, African-American women
are underrepresented in genetic studies
of breast cancer. The study, led by Laura
J. Bierut, MD, Alumni Endowed Professor
of Psychiatry, and Foluso Ademuyiwa,
MD, assistant professor of medicine, is
examining the distribution of mutations
in genes known to increase cancer risk.
The hands-on experience is teaching
students about genetic testing in
clinical care.

M

ice that vocalize in a
repetitive, halting pattern
similar to human stuttering
may provide insight into a condition that has
perplexed scientists for centuries, according
to researchers at the School of Medicine and
the National Institutes of Health (NIH).
Initially attributed to nervousness,
stress or even bad parenting, stuttering is
now recognized as primarily biological in
origin, although anxiety can exacerbate
the condition.
Some people who stutter have a
mutation in a gene called Gnptab (for
N-acetylglucosamine-1-phosphate
transferase alpha and beta). With
Dennis Drayna, PhD, and colleagues at
the National Institute on Deafness
and Other Communication Disorders,
the researchers created mice with a
corresponding mutation in the same gene.
These mice vocalized in an abnormal
pattern characteristic of human stuttering.
The animal model of stuttering can help
scientists understand the molecular and
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neurological basis of the disorder, and
potentially develop treatments.
“Speech is obviously a unique human
capacity, but the patterns of speech are
built out of simpler building blocks,” said
Tim Holy, PhD, an associate professor of
neuroscience and the paper’s senior author.
A key characteristic of stuttering is the
presence of hesitations. The researchers
developed an algorithm to analyze the
length of pauses in the spontaneous
vocalizations of 3- to 8-day-old mouse
pups. They found that mice carrying the
mutation exhibited longer pauses than
those without the mutation.
The researchers applied the same
algorithm to recordings of people talking,
some of whom stuttered and some of
whom did not. The algorithm accurately
distinguished the two groups.
Other than in their vocalizations, the
mice with the mutation were normal. In this
respect, the mice with the mutation are
like people who stutter — indistinguishable
from nonstutterers in all but speech.

ROBERT BOSTON

Mice offer new insights into human stuttering

Senior scientist Terra Barnes, PhD, and Tim Holy, PhD,
associate professor of neuroscience, hold mouse pups.
It is not clear how the gene relates to
speech. It is known to be involved in the
pathway that degrades molecules inside
the cell.
“It could be that the mutation very
mildly compromises the function of the
protein, but there’s a set of cells in the brain
that is exquisitely sensitive, and if you ever
so slightly compromise the function in those
cells you get the observable behavioral
deficit,” said Holy. “We just don’t know yet.”
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Using advanced technology, physical
therapy and orthopedic surgery
researchers Michael Harris, PhD, and
Marcie Harris-Hayes, PT, DPT, MSCI,
study movement in 3D. Cameras
with near-infrared light capture
motion-reflective markers placed on
patients with musculoskeletal and
neuromuscular disorders.
8 Washington University School of Medicine
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Movement
redefined
By adopting movement science as a central tenet, the
Program in Physical Therapy has reshaped its profession.
BY GAIA REMEROWSKI

Walking, rising from a chair, reaching for a book —
all are simple, everyday movements that many of us
take for granted. But for the faculty of Washington
University’s Program in Physical Therapy, movement
is not something to be taken lightly; it is a central
tenet of health.
The physical therapy (PT) program is a national
leader in the study of movement and how improper
movement leads to injury and impairment. With an
emphasis on diagnosing — rather than simply treating
patients — the program is changing the way the
profession is viewed.
More than three decades ago, faculty members
implemented, and have continued to refine, the
“movement system” as the basis for the program’s
research, educational and patient care initiatives.
“At Washington University the movement system
really is at the core of all that we do,” said Program
Director Gammon Earhart, PT, PhD. “That is unique
relative to most other physical therapy programs.

outlook.wustl.edu
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O

ur goal is to better understand how the
movement system works in health and
disease and to understand what we as physical
therapists can do to intervene and optimize
people’s function through movement,” she added.
In 2013, the American Physical Therapy
Association (APTA), the leading PT organization,
announced it also had adopted the movement
system as the foundation for the profession.

“

FOGLINE FEATURES

The human
movement system
Just as neurologists are defined
by their study of the nervous
system or cardiologists by their
focus on the heart, PT program
leaders believe physical
therapists should be defined
by their study of the movement
system. The program defines
the human movement system
as a collection of body systems
(pulmonary, cardiovascular, endocrine,
nervous and musculoskeletal) that interact
to produce and support movement. Shirley
Sahrmann, PT, PhD, FAPTA, professor emerita

10 Washington University School of Medicine

of physical therapy, has developed and promoted
the human movement system both in Washington
University’s program and in the profession.
As an active, athletic kid who grew up in the
polio era, Sahrmann was deeply affected by stories
of people who couldn’t participate in sports or
even walk. She has devoted her 50-year career to
understanding movement and helping people stay
as active as possible throughout their entire lives.
Early on, Sahrmann realized she could reduce
pain in patients with musculoskeletal issues by
adjusting their movements. “I had to pay a lot
more attention to why patients were not moving
correctly,” Sahrmann said. This prompted the
need for standardized exams and more accurate
methods to research and measure movement,
which were lacking in the school’s PT program
at the time.
So Sahrmann literally wrote the book on the
movement system — actually two books, both of
which are used in the program’s classes and by
health-care professionals worldwide. Sahrmann
and others have pushed the field to adopt and
associate itself with the movement system.
With the help of her colleagues, she succeeded
in getting a definition of the movement system
into Steadman’s Medical Dictionary and
continued to lobby for its implementation
at conferences and in professional circles.

Autumn 2016

Over the years, the Washington University
program has standardized ways to research and
diagnose various movement impairment disorders
outlined by Sahrmann and others. Sahrmann’s
textbooks, considered the gold standard for
movement system impairment diagnoses,
contain precise diagnostic terminology.
However, some of the more than 200,000
licensed PTs in the U.S. today are working
within their own diagnostic frameworks,
resulting in confusion. For example, universities
that study movement might label their work
as “biomechanics” or “pathokinesiology” (the
study of abnormal movements), rather than
Washington University’s term “movement
impairments.” This is one reason why the
profession needs a uniform classification
system, said APTA President Sharon Dunn,
PT, PhD, OCS.
Despite adoption by the APTA in 2013, there
are still challenges in getting movement system
diagnoses to the patient level and developing a
nomenclature that is backed by science. Dunn
noted that Washington University’s program is
leading the way and improving patient care.
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Diagnosis vs. treatment
With most injuries, patients must first see a
medical doctor before consulting a physical
therapist. The doctor makes a diagnosis such as
“low back pain” and refers the patient for therapy
services. Traditionally, PTs have used treatments
such as massage, heat and exercise to help ease
the patient’s pain and restore mobility. In this
longstanding scenario, PTs treat, rather than
diagnose, their patients.
Faculty members at the School of Medicine
are working to change this limited view of
PTs as treatment technicians, advocating
they instead should be seen as diagnosis-based
practitioners with deep expertise in the field
of movement science. The movement system
provides the framework for PTs to establish
themselves as movement impairment diagnosticians.
For example, Sahrmann said, “low back pain”
is not a diagnosis; it is a symptom. The underlying
cause still must be determined. “You can make
people feel better immediately,” Sahrmann said,
“but they’re going to come right back because
relief doesn’t last unless you really get to the root
of the problem.
“Acute pain problems often are just the first
warning of a more progressive issue.”

Above left: Gammon Earhart,
PT, PhD (left), director of the
Program in Physical Therapy,
and Jennifer Stith, PT, PhD,
LCSW, director of education,
meet in the recently renovated student lounge that
moved from the basement
to the top floor of the 4444
Forest Park Building.
Above: Recent PT graduate
John Huang performs a
practice exam on medical
student Christine Averill,
while Associate Professor
Suzanne Cornbleet, PT, DPT,
observes. The majority of
faculty who teach clinical
courses also are actively
engaged in clinical care.

Outlook 11

The program has ranked in the
top 1 percent for two decades.
Often the root of musculoskeletal pain stems
from repeated incorrect movement in a patient’s
everyday activities such as sitting, lifting and
walking. Proper diagnosis requires a thorough
exam that takes into account a person’s natural
way of moving.
Following an exam, a physical therapist might
change the “low back pain” diagnosis to “lumbar
flexion syndrome,” a condition in which the low
back is more flexible than the hips, causing
movement imbalances. “So we go through our
well established movement diagnostic tests and
we show the patient that if you bend in your hips
and not in your back, you don’t get symptoms,”
Sahrmann said.
Upon understanding the cause of movement
impairments, a trained PT can demonstrate the
correct way to perform regular activities.
Washington University studies show that
patients continue performing these types of
everyday life exercises more often than ones that
fall outside of normal routines. Patients are more
likely to practice the proper way to get up from
a chair — something they must do on a regular
basis — than perform specific low back stretches
requiring them to lie on a mat.

Professor Emerita of Physical Therapy Shirley Sahrmann, PT, PhD, FAPTA (left),
has written two textbooks on movement system impairments that are referenced
worldwide. Former student Maiko Morotani, PT ’05, translated one of the books
from English to Japanese and recently traveled with Sahrmann to Japan.
12 Washington University School of Medicine

Sahrmann also argues the physician referral
requirement needs to change. Many states require
physician referral for therapy, though some states,
including Arizona, Iowa, Kentucky, Maryland,
Massachusetts and Vermont, have moved toward a
self-referral model. Missouri has yet to follow suit.
John Metzler, MD, an associate professor
of orthopaedic surgery and of neurology who
refers many patients to Washington University for
physical therapy, wholeheartedly agrees that PTs
are more than technicians. “Most physical therapists
have a much broader knowledge of musculoskeletal
problems than the average physician because that’s
their area of expertise,” he said. “Washington
University has excellent therapists who are
methodical in how they approach patients. They
have a very systematic way of evaluating how
patients move, then trying to correct those
movements and giving very directed exercises.”
Metzler credits the program’s strong research
focus and evidence-based practices.

Moving research forward
Movement science research is a key part of
Washington University’s program, which is one
of the top-funded in the country. In 2015, the
program received more than $3.5 million in
research funding, said Michael Mueller, PT,
PhD, FAPTA, the program’s director of research.
According to the Web of Science, an industry
index that compiles publication citation statistics,
the program also had more papers cited than any
other PT program in the U.S.
“All of our research relates in some way to
movement,” said Earhart, who, as president of
the APTA section on research, helps translate
the program’s research results into practice.
Program research ranges from basic studies of
how movement occurs on a cellular level all the
way to a systems level.
For example, researcher Todd Cade, PT, PhD,
is looking at muscle metabolism and function in
patients with Barth Syndrome, a genetic disorder
that leaves sufferers weak and unable to exercise.
Earhart is leading studies that examine the
effects of dance and other exercise on improving
Parkinson’s disease symptoms. Other trials, such
as a study led by Linda Van Dillen, PT, PhD, are
exploring the effects of training people with low
back pain to modify their movement during daily
activities versus having them perform traditional
strength and flexibility exercises.
Autumn 2016

This research focus is one of the many educational
benefits for students, Earhart said. “We are able
to attract outstanding students who are drawn to
Washington University because of an environment
that has a research-intensive focus with faculty
who are internationally and nationally recognized
for their contributions to the literature and the
evidence base for physical therapy,” she added.
Currently ranked No. 1 in the country by U.S.
News & World Report, the program has been in
the top 1 percent for two decades.
Today, all students in the program complete
a doctorate in physical therapy (DPT). But this
wasn’t always the case. Susan Deusinger, PT, PhD,
FAPTA, who retired in 2014 after 26 years as
program director, led Washington University’s
progression from a baccalaureate-level educational
program to a DPT track, which takes about
three years and combines clinical, research and
classroom learning. More recently, the APTA
has mandated that all academic PT programs
offer the DPT, a prerequisite to becoming a
practicing therapist.
Another major draw for students is the
program’s clinical practice, staffed primarily
by faculty, said Beth Crowner, PT, DPT, NCS,
MPPA, director of clinical practice. “The fact
that the people who teach in our clinical courses
are still actively engaged in clinical care is a big
differentiator for us relative to many PT schools.”
Students spend part- or full-time in the clinic
with faculty during clinical rotations.
With such strengths in research and the clinic,
students come away with a strong foundation
in movement system diagnoses. “This program
has a rich history of mentoring and developing
leaders in the profession,” Dunn said.
The program also shares its research and
clinical advances through continuing education
initiatives such as an upcoming APTA movement
system summit. The summit joins together
representatives from U.S. physical therapy
programs to think about the movement system
and how it can be implemented in curricula,
research and practice.
“I think Washington University’s program
will continue to be a leader as the movement
system becomes more prominent on a national
scale,” Earhart said. “And we have a lot of
opportunity to help the public better understand
who we are and what we contribute.”
outlook.wustl.edu

Diagnosing movement
impairments

P

hysical therapy
clinic associate Jesse
Civello, PT, DPT (right),
uses standardized exams
developed at Washington
University to determine
whether or not a patient
has a movement
impairment disorder.
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Educational benefits
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Resistance
is inevitable
Nature can — and will — overcome any antibiotic.
Researchers are working to ensure we stay one step ahead.
BY J U L I A E VA N G E LO U S T R A I T

With increasing reports of superbugs that are
resistant to virtually all antibiotics, experts warn
of a return to the pre-antibiotic era. In that future,
routine surgeries and minor conditions, such as a
scraped knee or urinary tract infection, could more
frequently result in serious infection or death. Those
with impaired immune systems — including cancer
and organ transplant patients — face the greatest risk.
Proposals to address the problem call for
judicious use of antibiotics, both by doctors and
in U.S. agricultural practices. While overuse of
antibiotics is a significant contributing factor,
experts say restrictive measures only will slow
the problem. Bacteria, in a quest for survival,
are continually adapting and mounting new,
clever defenses against these drugs.
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Microbiologist Gautam Dantas,
PhD, is sequencing vast
quantities of bacterial DNA
in efforts to understand and
thwart antibiotic resistance.
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icrobiologist Gautam Dantas, PhD,
argues that the only sustainable
solution is to nurture a robust drug
discovery pipeline. Informing his view is his lab’s
extensive body of work documenting the genetics
of antibiotic resistance in diverse environments,
from hospital neonatal intensive care units, to
rural farming villages, to urban slums, to an
Amazonian tribe cut off from civilization. His
overwhelming conclusion: Regardless of habitat,
microbes are “chock-full” of DNA that gives them
the capacity to survive chemical onslaught.
“Resistance is inevitable,” said Dantas, associate
professor of pathology and immunology. “No drug
we design is going to permanently prevent resistance.
The only way to fight resistance is to find new drugs.
And we have to do it continually. Microbes thrive
everywhere, including miles below the Earth’s crust
or surrounded by radioactive waste.

Microbes thrive everywhere, including
miles below the Earth’s crust or
surrounded by radioactive waste.
“Their extreme versatility is a reminder that
microbes can do incredible things,” he added.
“They have insanely large population sizes and can
divide at incredible rates. What enables all this is
incredible chemistry. Bacteria are the best chemists
we know. We need to respect that ability.”
Antibiotics destroy or weaken bacteria in
several different ways, including breaking up the
cell wall, restricting replication and inhibiting
the production of needed proteins.
In an ever-escalating arms race, superbugs have
accumulated genes that, in turn, interfere with
antibiotics. These strategies include pumping the
drugs out of bacterial cells, blocking the drug
from its target, and breaking apart the antibiotic
molecules themselves.
The notorious methicillin-resistant
Staphylococcus aureus (MRSA), for example,
destroys methicillin and similar drugs by breaking
the drug’s key chemical bonds. In destroying the
drug, MRSA protects not only itself but other
bacteria nearby that lack such defenses.
The concept of microbes as chemists is highlighted
by the 1928 discovery of penicillin. Like penicillin,
which is made by a type of mold, most antibiotics
that people have harnessed to kill dangerous
16 Washington University School of Medicine

bacteria are products of other microbes, usually
harmless organisms that live in soil. To survive,
bacteria must prevent harm via their own chemical
arsenals. Over millennia, microbes have evolved the
capacity to produce these chemicals as part of
their self-protection and communication strategies.
“If you study old sources of soil bacteria that
have no exposure to humans — microbes frozen
in permafrost for millions of years, for example —
some of these bacteria have genes that confer
resistance to chemicals that we rely on as modern
antibiotics,” Dantas said.
With this history in mind, Dantas and
colleagues sought to understand the extent of
antibiotic resistance in current soil bacteria.
Studying 18 different soil samples from across the
U.S., the researchers concluded that soil bacteria
contain a massive biochemical capacity to resist
even our most potent antibiotics. However, they
found that most of these genes fortunately are not
poised to jump into bacteria that cause disease.
Along with this presumably good news, the
researchers made a worrisome discovery — a
novel set of enzymes manufactured by soil
bacteria that confer resistance to tetracyclines,
a vitally important class of broad-spectrum
antibiotics. The researchers also noted that these
enzymes — which they dubbed tetracycline
destructases — are coded into mobile parts of the
bacterial genome that are easily shared, even
between distantly related bacteria. It is mobile
resistance genes that concern Dantas most.
“We know such genetic transfers have already
happened and will continue to happen,” Dantas
said. “And we now have the tools to predict the
chances that these bacteria will intermingle with
microbes that cause disease, potentially transferring
these resistance capabilities to the clinic.”
Glimpsing the scope of microorganisms’ genetic
capacity to evade antibiotics may be alarming, but
in these vast databases of bacterial DNA, Dantas
sees the blueprints for the design and development
of new antimicrobial drugs. In theory, if you can
determine how bacteria evade a specific drug, you
can develop ways to thwart them.
In one drug-development strategy, Dantas and
associates are using genetic sequencing to identify
and track the genes at highest risk of making
disease-causing bacteria resistant to important
antibiotics. The highest-risk genes — and Dantas
puts the tetracycline destructases in this high-risk
group — then become targets for the design of
new compounds that inhibit these genes and
their products.
Autumn 2016
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nterconnected ecological habitats make it easy for antibiotic
resistance to spread. Resistant strains living in soil get passed
on to humans through various routes. Gautam Dantas, PhD, and
his team have studied diverse environments, including densely
populated slums surrounding Lima, Peru, and a tiny subsistence
farming village in El Salvador. They uncovered numerous “hotspots”
of resistance gene transfer, including chicken coops and sewage
treatment systems. El Salvadoran villagers have close interactions
with their chickens, giving the birds freedom to roam into cooking
areas (below left). In Lima, sewage is processed in a wastewater
treatment plant (center), and then the semi-clean gray water is
used for irrigation throughout the city (right).
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GIORDANO SOSA-SOTO

Interconnected
habitats harbor
— and spread —
resistant bacteria
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Old drug, new tricks
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Many approved antibiotics have been taken off the
market because they are no longer effective. If new
genomic strategies can be used to unravel the reasons
an antibiotic has stopped working, compounds
can be developed that target the resistance, rather
than the bacteria. Once the resistance is knocked
down, in theory, old drugs could work again.
Tetracyclines are old drugs that are widely
used in medicine, veterinary care and agriculture,
especially in fish and shrimp farming operations.
With such indiscriminate use, tetracyline
resistance already exists in the clinic. But unlike
MRSA, which destroys methicillin, tetracyclineresistant bacteria in the clinic currently evade the
drug without breaking it apart. Dantas worries
that the prospect of bacteria carrying tetracycline
destructases, which, as the name suggests, destroy
tetracycline, may change that, elevating this type
of resistance to MRSA-like status.

Indeed, tetracycline destructases’ genetic
mobility and ability to destroy a drug widely
used in the clinic and in agricultural settings
have led Dantas to predict a major resistance
problem in the future. Such resistance also could
compromise new tetracycline-based drugs that
are being considered for imminent clinical use.
While such data sounds ominous, it also presents
an unprecedented opportunity: the chance to
design strategies to fight this type of tetracycline
resistance before it begins circulating in hospitals.
“We are exceptionally reactionary in our
response to antibiotic resistance,” Dantas said.
“We only take action after people have died.
Until recently, we did not have the tools to
determine where this resistance was coming from.
Now, we understand that we live in interconnected
habitats that harbor different kinds of bacteria.
“We can track the genes that confer antibiotic
resistance and begin to develop an understanding
of how they move,” he added. “With that information,
we can calculate the risk that they may transfer to
bacteria that cause disease. This new understanding
has led us to predict that the tetracycline destructases
are at high risk of transferring to the clinic in
the future.”
The researchers’ argument was sufficient to
convince the National Institutes of Health (NIH)
that tetracycline destructases are worthy of further
research. Earlier this year, the NIH awarded a $3.6
million grant to Dantas and collaborators Niraj
Tolia, PhD, associate professor of molecular
microbiology, and Timothy Wencewicz, PhD,
assistant professor of chemistry. They are working to
develop inhibitors against tetracycline destructases.
Such inhibitors could let tetracycline remain an
effective antibiotic even if or (as Dantas argues)
when bacteria carrying tetracycline destructases
begin to emerge in health-care settings.

Two are better than one

Superbugs accumulate genes that interfere with antibiotics.
These genes give microbes the ability to: (a) make impermeable
cell walls; (b) block drugs from their targets; (c) break apart the drug
molecules; (d) pump drugs out; and, sometimes, all of the above.
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Because developing new inhibitors from scratch
takes time, and patients are facing deadly
antibiotic-resistant infections today, Dantas
proposes a second strategy: high-throughput
screening to test combinations of existing drugs.
Attacking resistant bacteria using synergistic
combinations of drugs can overwhelm defenses
in ways that single drugs cannot.
Such “cocktails” that leverage drugs already
approved by the Food and Drug Administration
could, in theory, move more quickly into clinical
use than novel compounds.
Autumn 2016
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Scanning electron
micrograph of methicillinresistant Staphylococcus
aureus (MRSA).

Dantas’ team found that a combination of three
drugs — meropenem, piperacillin and tazobactam
— cleared mice of MRSA infections that normally
kill them in less than a day. All three drugs belong
to a class of chemicals called beta-lactams,
considered obsolete against MRSA for decades.
Dantas showed that the three drugs in tandem
render the bacteria vulnerable to attack, making it
difficult to resist the onslaught. If the bacteria
become resistant to one component of the tripledrug cocktail, they are rendered more sensitive
to one or both of the others.
“This is a parallel strategy to the tetracycline
destructase story,” Dantas said. “In the first case,
we’re talking about studying ecology and genetics
to design new inhibitors. In the second, we’re
rescuing existing classes of antibiotics that are
useless against certain bacteria when given
separately. In both cases, we are anticipating the
bacteria’s resistance strategies. That is our theme:
When you go after new treatments, think about
resistance from the beginning.”

Lessons learned
Yearly in the U.S., antibiotic-resistant infections
plague more than 2 million people, killing some
23,000, according to the CDC. Dantas said these
hard-fought battles offer lessons in how bacteria
evolve resistance.
In a third strategy, Dantas is working directly
with hospital microbiology labs to sequence drugresistant infections as they emerge and identify
how they evade antibiotics. “There are a large
number of emerging resistance strategies, and
we just don’t know how they work,” Dantas said.
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Carey-Ann Burnham, PhD, is medical director
of the clinical microbiology lab at Barnes-Jewish
Hospital. She and Dantas are studying one
particularly puzzling case in which a heart patient
developed an infection that, in less than three
weeks, became totally resistant to an important
antibiotic called daptomycin.
“The magnitude of the change in this bacteria’s
ability to resist daptomycin had never been reported
before,” Dantas said. “Typically, a bug might develop
enough resistance that the dose would need to be
increased two-fold or four-fold, for example. In
this patient’s case, the dose would have needed to
increase 1,000-fold to kill the bacteria.”
The patient survived, but only after six weeks of
treatment with linezolid, a toxic antibiotic of last
resort. Courses longer than one month can cause
serious complications, including bleeding and
vision loss.
To understand this particular superbug,
Dantas and his colleagues are immersed in
their molecular detective work.
“We are excited to apply our knowledge and
tools to help patients,” Dantas said. “We began by
surveying bacteria in the environment, even
though that work initially seemed far removed
from any clinical application. But that research has
helped us determined that resistance is everywhere.
“Rather than seeking irresistible antibiotics,
perhaps the best strategy is to treat resistance as a
given, use our tools to anticipate where it will come
from, and develop proactive strategies to address it
before it becomes a problem in patient care.”
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Learning
labs

For most medical students, there’s a major obstacle
to doing research: being in medical school.
Not at Washington University.
B Y D E B PA R K E R

Medical student Margery
Gang collaborates on an
acute myeloid leukemia
project with Timothy
Ley, MD, the Lewis T.
and Rosalind B. Apple
Chair in Oncology.
outlook.wustl.edu

On top of mastering enormous volumes of material,
sitting for exams, going through clinical rotations
and applying for residencies, medical students don’t
have a lot of spare time.
Yet health-care professionals recognize the
importance of research experience, even for students
headed into clinical practice. Strong research skills
and strong clinical skills are inextricably linked.
Doctors must scrutinize an endless barrage of
primary scientific literature; only by thinking
critically can they determine the best course for
individual patients.
At the School of Medicine, student research
opportunities abound — in basic, clinical and
translational science, global health, device and
technology development, and in nearly every
discipline. More than 2,100 faculty mentors stand
ready to guide.
Orchestrating the dizzying array of options and
playing master project matchmaker between student
and faculty mentor is Koong-Nah Chung, PhD,
associate dean for medical student research.
Outlook 21
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Researcher at heart:
Associate Dean Koong-Nah
Chung, PhD, meets with
every single student and
tirelessly dedicates herself
to finding and supporting
research opportunities.

An upswing in involvement
Although involvement is optional, more than 95
percent of students complete a research project
during their time at the medical school.
“Research is an essential part of the MD
curriculum,” said Michael M. Awad, MD, PhD,
associate dean for medical student education and
associate professor of surgery. “Here, they gain the
ability to perform scientific discovery and begin a
journey of lifelong learning, priming them to
become future leaders in academic medicine.
“Very few schools with optional research
programs have such a high student participation
rate, a fact noted positively during our recent
medical school accreditation site visit,” he added.
The school’s robust research environment plays
a key role in recruiting and molding students.
Via in-house surveys, applicants cite “research
opportunities” as one of the top two reasons for
selecting Washington University.
In surveys of U.S. medical students conducted
by the Association of American Medical Colleges,
Washington University respondents say they
incorporate research into their studies at double
the national rate. Further, they publish at twice
the national rate. Sixty percent of Washington
University medical graduates lands careers at
academic medical centers versus 30 percent
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nationally. “We truly are training future
physician-scientists,” Chung said.
Fifteen years ago, just one-third of Washington
University medical students participated in
research, supported at the time by a small
National Institutes of Health (NIH) grant.
There wasn’t a dean of student research or a
centralized office to coordinate project partnerships.
Chung — who was appointed research assistant
professor in 1996 and assistant dean in 1999 —
became that point person and began advocating
for increased participation. Five years ago, she
formed the Office of Medical Student Research.
Chung and her team members, including
coordinator Rosalyn Bradshaw-Robinson, and
administrative assistant Heather Bartels, work
tirelessly to create an infrastructure that spawns
hundreds of research projects. To-dos include:
soliciting funding; tracking the work of 2,000-plus
principal investigators; and meeting one-on-one
with students. The office maintains comprehensive
listings of trainees over the last 20 years and their
funding sources and published works.
“She (Chung) is such a researcher at heart,”
Bradshaw-Robinson said. “She attacks everything
with such attention and detail.”
Thomas Baranski, MD, PhD, associate professor
of medicine, agrees. “Dean Chung has been
essential in fostering research opportunities for
medical students. She has succeeded because of
her own love of medical research and her passion
to see our medical students get a chance to do
their own research.”
In today’s competitive funding environment,
only 7 percent of NIH grant submissions receive
approval. However, Chung’s initial five-year NIH
grant from 2001 has been renewed four times,
cumulatively bringing in $3 million for student
research. As a result, every student participating
in a summer research project has been fully
funded for the past 16 years through this grant
and financial support from the dean’s office.
This spring, Chung learned that the grant has
been extended through 2021. The 1,200-page NIH
grant application, which requires nine months of
preparation, received a nearly perfect score.
Lengthier research projects are not fully covered,
but Chung’s team leverages 20-plus funding
mechanisms — including various foundations and
private grants — and guides students in writing
applications for financial support.
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‘We truly are
training future
physician-scientists.’
— Koong-Nah Chung, PhD
For Chung, it all comes down to customer
service. Seamless experiences for mentee and
mentor boost participation and enrich the
institution. “Definitely the word has gotten out,”
Chung said. “Any medical student who wants to
participate can. That commitment is loud and clear
to students. If you want to do research, we make it
easy here and you can do significant research.”
To get the process started, Chung and Robinson
meet personally with students. Because Chung
also serves as admissions subcommittee chair, her
mornings, October through February, are reserved
for meeting prospective students. Her afternoons
are spent helping current students better understand
their interests as they seek meaningful projects.
As someone who knows all of the students and
many of the faculty members, Chung strives to
match temperaments. Finding an ideally suited
mentor can forever alter a student’s life aspirations.
Rachel Goldberg, now a third-year medical
student, met Chung during the admissions
process and later sought her help in securing an
otolaryngology research project. She echoes the
thoughts of many students who describe Chung as
one of the medical center’s most beloved members.
“Dean Chung is amazing,” Goldberg said.
“She is one of the warmest people I know. She
is what I thought about when I thought about
Washington University. I don’t know anybody
in the country who does what she does.”
For students on a hectic training path, this
support makes all the difference. “When I was
looking at medical schools, I didn’t hear of
another medical school that was able to provide
that amount of funding to students,” Goldberg
said. “I didn’t have to worry about finding funding
for research. It definitely was a draw. I just needed
to concentrate on my education.”

Medical students present their work
at the annual poster session.
outlook.wustl.edu

Pathways to
research
Washington University medical
students conduct research through
four options:
Summer Research Program, a three-month
introduction to research
Yearlong Research Program, in which
students “stop the medical school clock” and
are released from courses to conduct one
year of in-depth research after their second
or third year of medical school. Tuition is
waived, and many students receive stipends.
Fourth-year elective, offering six to
12 weeks of full-time, daily research for credit
Medical Scientist Training Program
designed for physician-scientists who wish
to earn a combined MD/PhD. The rigorous
program takes six to eight years to complete;
tuition is waived, and students receive an
annual stipend.
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Research opportunities extend
from the bench to the bedside.
Above, Alison G. Cahill, MD,
MSCI (left), associate professor
of obstetrics and gynecology,
confers with medical student
Fayola Fears about a research
project focused on infant
neurodevelopment.

Lasting contributions
Faculty here — including some of the world’s
experts in their respective fields — are eager to
welcome the 500 MD and nearly 600 PhD students.
“Over the years, I’ve not had one faculty member
who didn’t want to host,” Chung said. “We are
successful because faculty are willing to mentor.
I’ve also had support from Deans William Peck,
Larry Shapiro and David Perlmutter and my
mentors Ed Dodson and Leslie Kahl.”
For faculty, it’s inspirational to have smart,
creative, hard-working students in their labs.
“Our faculty are drawn here and retained here
because of the ability to work with great students,”
Chung said.
Jay F. Piccirillo, MD, FACS, recalls the
outstanding mentorship he received during
fellowship training at Yale University from Alvan
Feinstein, the grandfather of clinical epidemiology.
Today, Piccirillo, a professor of otolaryngologyhead and neck surgery, enjoys serving a similar
role in trainees’ lives and hopes to inspire them to
become “change agents” in medicine.

Many of the mentor-mentee
relationships evolve into decadeslong collaborative partnerships.
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“The most important part of being a mentor is
listening to mentees, supporting them through
their situation, whether that is a research project
or personal life challenge,” Piccirillo said. “Now
that I have been at the medical center for more
than 20 years and have interacted with so many
students, I feel very confident that I have valuable
information to share.
“I love to be available and help, when asked,
for important decisions in our students’ lives,
like specialty choice or whether to pursue an
academic research career.”
Many such relationships evolve into decadeslong collaborative partnerships. “The mentor has
the reward of witnessing the intellectual growth
and maturation of the mentee,” said Michael
Avidan, MBBCh, professor of anesthesiology and
cardiothoracic surgery. “It is particularly
rewarding when my students have advanced in
their careers, developed their own research
programs, and have demonstrated prowess as
independent investigators.
“I believe that the most important contribution
we make to society as faculty members is the
mentorship and guidance we provide to our
students.”
Stereotypes persist of the lonely scientist toiling
away in a lab, performing repetitive tasks and
interacting only with pipettes and test tubes.
It’s Chung’s goal to dispel such notions and
help students through their initial hesitation
and self-doubt. Research, she said, is connected
with independent thinking, creativity, teamwork
and, most importantly, discovery.
Autumn 2016
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Redefining medical practice
Katherine Santosa admits she found the idea
of research intimidating as a fledgling medical
student. This all changed following a mentorship
with Susan Mackinnon, MD, the Shoenberg
Professor of Plastic and Reconstructive Surgery
and chief of the Division of Plastic and
Reconstructive Surgery.
“The decision to spend one year in the laboratory
under Dr. Mackinnon has undoubtedly been one
of the most important decisions I have made in
my career,” Santosa said.
“Dr. Mackinnon is a brilliant surgeon-scientist
who generated research questions directly based
on the challenges she encountered in the clinic
and operating room,” she added. “Then, she
would take the data and translate the work from
the laboratory back to her patients in the clinic.
As a medical student, I witnessed the tremendous
impact research could have on improving
outcomes for surgical patients.”
Following a surgical residency at the
University of Michigan, Santosa, MD, has
returned to Washington University as a plastic
surgery resident and research fellow under plastic
surgeon Alison K. Snyder-Warwick, MD.
Now, Santosa has new aspirations: to care
for patients with facial paralysis and complex
peripheral nerve injuries, and to have a
laboratory that will improve understanding
of neural regeneration.
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Through research, abstract concepts taught in
the classroom become less elusive. Students gain
an appreciation for the vigor of research — how
to create hypotheses and test them and to
meticulously record their work. Perhaps, most
dauntingly, they learn about failure.
“In science, it’s a natural thing to encounter
failure; it’s normal to encounter failure nine out
of 10 times,” said Brian Kim, MD, assistant
professor of medicine and dermatology. “For
many students, especially students at great
institutions like Washington University — to their
credit — they haven’t often encountered failure.
It’s something all scientists have to tackle. I feel,
as a PI, like much more of a coach than a teacher.
“It’s about having the right mentality and
viewing science not as a sprint, but understanding
that it’s a marathon and that we have to
continuously put in the work,” he added.
Santosa said research quickly taught her
humility and resilience. “Designing experiments,
getting presentations and publications accepted,
and obtaining grants are all essential components
of the process but they are exceedingly difficult to
do,” she said. “While caring for patients certainly
teaches you similar lessons, I think failure in
research is more common than it is in the clinics,
and the only way to succeed is to persevere.”
As part of the program, students must explain
and defend their work in a poster presentation.
This fall, the research office will sponsor its 11th
annual WUSM Research Symposium and Poster
Session on campus. The event draws many
inquiring minds from the medical center
community. Students also are encouraged to
travel and present at professional meetings.
Piccirillo said he was overjoyed to see the
expression of personal pride and satisfaction on
the face of one of his mentees — who suffered
from social anxiety — after delivering a flawless
research presentation at a national meeting.
According to Kathryn Diemer, MD, assistant
dean for career counseling and associate professor
of medicine, such polished, prepared Washington
University students fare well in the fiercely
competitive national residency match, earning
coveted training spots. All of this leads to a
generation of more knowledgeable,
well-rounded physicians.
As Chung says, “When given the tools, our
students can fly.”
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David H. Perlmutter, MD, executive
vice chancellor for medical affairs
and dean of the School of Medicine,
talks with graduate research assistant
Dolonchampa Maji in the new 4515
McKinley Research Building.
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Personalizing
medicine
A leadership vision for advancing human health by
leveraging core strengths at the School of Medicine.

David H. Perlmutter, MD, is closing in on his
first year as executive vice chancellor for medical
affairs and dean of the School of Medicine.
Originally from New York, Perlmutter has
moved to St. Louis three times — first as a medical
student at Saint Louis University, then as a faculty
member in pediatrics at Washington University,
and now as dean. Most recently, he served as the
Vira I. Heinz Endowed Chair of the Department
of Pediatrics at the University of Pittsburgh and
as physician-in-chief and scientific director of
Children’s Hospital of Pittsburgh.
Personalized medicine is No. 1 on his priority
list, and he believes the School of Medicine is
TIM PARKER PHOTOS
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positioned to be a leader in the field.
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Tell us about your
medical education at
Saint Louis University.
I didn’t realize my own potential for
a long time. I thought I wanted to go
to medical school and got into Saint
Louis University, off the wait list. I didn’t
unpack for six months because I didn’t
think I would make it. But by the
time I graduated, I had become a
very different person. At graduation,
I received so many awards that my
family just couldn’t get over it; they
thought I was a totally different
human being.
Basically, what had happened —
and I didn’t fully realize this until years
later — was that I had developed a love
of medicine and of learning. It was
in medical school, here in St. Louis,
where I found that I could work with
unbelievable capacity, discipline and
focus and that I had an insatiable desire
to learn more about physiology, biology
and the medical profession overall.

In 1983, you joined the
Harvard Medical School
faculty, but left for a position at
Washington University. Why?
At Harvard, I was extremely fortunate
to work in Dr. Harvey Colten’s lab.
He was a phenomenal scientist and
mentor, and it was while working with
him that I truly realized that biology
was a key to understanding human
diseases. When he took over as head
of the Department of Pediatrics at
Washington University in 1986, he
asked me to come along. It might have
seemed an odd decision — I didn’t
have grant funding, my wife and I had
28 Washington University School of Medicine

There’s an uncommon level of support
at the university for physician-scientists.
a baby and another on the way, and
I didn’t expect to go back to St. Louis
— but I couldn’t say no, especially
after talking with the amazing people
here. I met with Phil Needleman,
Philip Stahl, Stuart Kornfeld, Jeff
Gordon, Stan Korsmeyer and on and
on. It was one giant after another
— and it wasn’t just this feeling of
being surrounded by intellectual
horsepower, there was a very evident
feeling of nurturing and community.
You come here and you become part
of the community. When I set up my
lab, I interacted with every single
department and with investigators
throughout the school. I became
friends and colleagues with so
many people who reached out to
me. I loved it here.

After 30 years in medicine
— first here and later at the
University of Pittsburgh —
what prompted you to return
as dean?
More than just one thing. St. Louis
is a wonderful city and is dear to my
family. One of the reasons I believe
Washington University has such
an incredibly successful medical
school is because of the deep sense
of community here. But also, there’s
an uncommon level of support at the
university for physician-scientists,
and that was a major draw for me.
The Medical Scientist Training
Program here is the best in the
world, and the physician-scientists

are treasured in a way you don’t
see anywhere else. Also, becoming
dean meant I could play a role in
making the changes and innovations
that are so important to health care
and biomedicine, and where better
to be at the forefront of what is
needed than Washington University?
There is so much going on here —
in advancing science and curing
diseases, in educating future doctors
and scientists, and in providing
excellent health care to people who
need us. The commitment, energy
and devotion you see here every day
are incredible.

Why are you focused on
personalized medicine?
Medicine treats many people in the
same way, even though they have
known differences in the course
of their diseases. The promise of
personalized medicine is that we
can become more sophisticated in
our understanding of each disease,
identify personal variations and tailor
therapy to those variations in a way
that is likely to be more effective.
Many opportunities have arisen as
genomic sequencing and editing
have become more affordable, from
developing new targets for drugs
to speeding the diagnosis of lifethreatening illnesses. Simply put, the
long-term objective is to give the right
treatment to the right patient with the
aim of saving and improving lives.
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How is Washington University
positioned to be a leader in
personalized medicine?
There are so many strengths at the
university in the area of personalized
medicine. We have centers for
achieving different kinds of genetic
sequencing here: a center that can
help researchers reproduce a disease
in a cell line or a mouse; a center
where scientists can make induced
stem cells; drug-focused centers
that will help investigators zero in
on therapeutics — the list goes on.
Each of these many centers and
the magnificent scientists who
work in them are keys to tackling
disease. I believe we need to continue
focusing on the many areas where
the university is an established leader
and to develop core facilities that can
rapidly incorporate new technology.
Right now, for example, we have
researchers working on personalized
vaccines to treat breast cancer and
melanoma. I believe we are at a
tipping point for understanding
human disease and improving
patient care. Washington University
is so well-positioned to advance
knowledge and improve health and
well-being. It is our responsibility
to embrace this opportunity for
the benefit of society.

How can personalized
medicine improve the
health-care system?
If we can realize at least some
parts of the dream of personalized
medicine, we will be treating people
in a much different way than we treat
them today. Personalized medicine
would allow us to provide a particular
therapy only to patients it would help,
sparing others from unnecessary
treatments and harsh side effects.
Meanwhile, other patients would
receive therapy specific to them.
So if only 20 or 30 percent of patients

The way I look at it, the biggest shot
we have at reducing health-care costs
is through our research.
outlook.wustl.edu

Dean Perlmutter with his wife, Barbara A.
Cohlan, MD, a professor in the Department of
Pediatrics specializing in newborn medicine.

with, for example, breast cancer are
receiving the most extensive and
expensive therapy, that should reduce
health-care costs and provide optimal
care. The same approach could be
applied to other diseases. And this
is a great place to figure these things
out because we have so much genomic
expertise and tremendous investigators
in cancer, immunology, the microbiome,
Alzheimer’s disease, age-dependent
degenerative diseases and other major
areas of emphasis.
The way I look at it, the biggest
shot we have at improving medical
care and reducing health-care costs is
through our research. There are many
incremental ways to reduce such costs
through process and changing how
we do things. But what will really
transform health care will come from
research, and, for me, personalized
medicine will be key.
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What else would you like
to see emphasized at the
School of Medicine?
I want to see discoveries benefit
our patients sooner, and I believe
this will require more attention to
commercialization. The genomic
revolution has positioned us to move
this forward in a more timely way,
and the university is working hard
to facilitate entrepreneurship in a
most conscientious way. This school
has always been noted for its great
collaborations, but I also want to
explore potential industry partners
for shared research programs.
Physician-scientist career
development is also very important,
particularly since the percentage
of physicians nationally who are
conducting research has been
dropping in recent years. And
another key emphasis for me
will be diversity and inclusion
throughout the Medical Campus,
from students, to staff, to faculty.

Nobody here is going to be satisfied
doing the same thing tomorrow that
he or she is doing today.
We need to improve diversity in our
workforce in particular and become
more successful at developing the
careers of minorities. It’s so important
to understand that we are richer as
a whole with varying perspectives.
Diversity and inclusion are imperative.
I also want to continue building
on our excellent faculty practice and
improving our ability to serve the
community. It’s an honor to provide
exceptional health care to so many
citizens throughout the St. Louis
region and beyond. I’ve become very
moved by how important our role is
as a safety net.

Now that you’ve been
here nearly a year, what
has surprised you most?
I was surprised at some of the
breathtaking science here. Even
though I knew great things were
going on at this school, I had no
idea how extraordinary the breadth
and the depth of the talent are
and, likewise, how exciting the
programs are. To a certain extent,
it’s daunting because I see myself
as being responsible for that now.
It’s very humbling. But what’s
exhilarating is that nobody here
is going to be satisfied doing the
same thing tomorrow that he or she
is doing today. Everybody here is
interested, like I am, in pushing the
envelope and being at the forefront
of new discoveries that ultimately
will benefit mankind. It’s an amazing
place to be, and I’m so excited and
fortunate to be a part of it.

Interview conducted and compiled by
writer Elizabethe Holland Durando
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notable

Tom Hornbein, MD
’56, delivered the MD
Commencement
address May 20.

Legend in climbing
Mountaineer-doctor shares wisdom gained from taking risks

I

n 1963, Tom Hornbein and Willi Unsoeld,
fellow American mountaineers, became the
first climbers to summit the world’s highest
peak — Mount Everest — via the dangerous
West Ridge. Fifty years later, the climb is still
hailed as one of the greatest achievements in
mountaineering. Only 12 other climbers have
ascended Everest by the West Ridge. Fourteen
have died in the attempt. Hornbein, who was
born in St. Louis and earned a medical degree
from Washington University in 1956, addressed
students at this year’s MD Commencement.
Mountains remain a powerful metaphor in
Hornbein’s life; they are the foundation on
which he has based most of his major decisions.
At age 13, Hornbein discovered the mountains
during a summer camp in Colorado. He went on
to major in pre-med at the University of Colorado
and became involved in mountain rescue
activities. After earning a medical degree back in
St. Louis, Hornbein completed an anesthesiology
residency at Barnes Hospital and a fellowship in the
lab of pulmonary researcher Albert Roos (who died
in 2007). Hornbein’s research focused on control
of breathing by hypoxia, as at high altitude, and
outlook.wustl.edu

’Accept risk, savor it as an
essential seasoning to becoming
a good doctor, a good parent, a
good you.’ — Tom Hornbein, MD ’56
other physiological stimuli (CO2, pH) on
peripheral and brainstem chemoreceptors.
Folllowing the Everest climb, Hornbein
joined the faculty at the University of
Washington School of Medicine in Seattle
and served as chair of the Department of
Anesthesiology from 1978 to 1993. Now a
professor emeritus, Hornbein and his wife,
Kathy, live in Estes Park, Colorado. At 85, he
still climbs the mountains around his home.
Hornbein advised students to view change
and risk as essential ingredients for professional
and personal growth. “As an anesthesiologist,
most of the time I had great control,” Hornbein
said. “Every now and then, things would bust
loose. The ability to stand still, to think clearly
in the middle of an emergency, to be a riskaccepter and not risk-averse is critical. ... I wish
you all grand adventures seasoned with a decent
dose of uncertainty,” he said.

Hornbein recounted his
adventures in “Everest:
The West Ridge.” A recently
released 50th-anniversary
edition includes photos by
expedition members and
a foreword by best-selling
author Jon Krakauer.
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Harnessing immunity

W

ashington University School of Medicine

A $10 million gift
establishes Bursky
Center for Human
Immunology and
Immunotherapy
BY JULIA E VANGELOU STRAIT

has received a $10 million gift in support of the
Andrew M. and Jane M. Bursky Center for

Human Immunology and Immunotherapy Programs.
Previously known as the Center for Human Immunology and
Immunotherapy Programs (CHiiPs), the center is dedicated to
understanding the immune system and its potential for treating
cancer, fighting infection and providing novel treatments for
autoimmune disorders and immune deficiencies.
The gift from Andrew M. and Jane M. Bursky also
supports an endowed distinguished professorship for the
center’s director, Robert D. Schreiber, PhD, the inaugural
Andrew M. and Jane M. Bursky Distinguished Professor.
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Michael S. Diamond, MD, PhD, Robert D. Schreiber, PhD,
and Wayne M. Yokoyama, MD, lead a team of investigators
working to develop immune-based therapeutics.

“Andy and Jane’s generous gift will be used not only to
support the innovative work of Dr. Robert Schreiber, but
also to benefit the distinguished team of researchers and
physicians who are members of the center,” said Chancellor
Mark S. Wrighton. “These scientists are making incredible
advances in the field of human immunology.”
Schreiber has led the center since its establishment in
2014 with a focus on nurturing the translation of basic
discoveries in the lab into new therapies for patients. Long
known for its role in fighting infectious disease, the immune
system has more recently been implicated in cancer and
for its overactive role in autoimmune conditions such as
rheumatoid arthritis, type 1 diabetes and multiple sclerosis.
“With the strength of the immunotherapy programs at
the School of Medicine combined with the sequencing power
of the McDonnell Genome Institute, this new gift will help
jumpstart major research initiatives in understanding and
developing new immune-based therapeutics for a broad
array of diseases,” Schreiber said.

New therapeutic strategies
Schreiber is well-known for his research in tumor
immunology and cell signaling. His work has been
instrumental in helping distinguish the conflicting
roles that the immune system can play in cancer, whether
protective when preventing tumor growth or detrimental
when unable to recognize and attack cancer cells. Fifteen
years ago, Schreiber and his colleagues introduced the
three-phase concept of cancer immunoediting. In the first
phase, dubbed elimination, early cancer cells are destroyed
by the immune system. Those cells that survive the initial
onslaught then enter the second phase, termed equilibrium,
characterized by a state of tumor dormancy. The final
phase — escape — occurs when the surviving tumor cells,
now adept at evading the immune system’s defenses, escape
the dormant state and begin to grow. New cancer immune
therapies may focus on priming and retraining the immune
system to once again attack these evasive cancer cells.
Schreiber and collaborators at Washington University
pioneered the use of genomics approaches to identify
mutant proteins uniquely expressed in a patient’s tumor
that can target the individual’s cancer cells for immune
destruction. This approach has formed the basis for major
ongoing translational programs at the School of Medicine
and elsewhere to test the therapeutic efficacy of personalized
vaccines in patients with cancers of the breast, brain,
lung, pancreas, prostate, melanoma and certain forms
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of lymphoma. Beyond cancer research, other leading
center investigators are studying important and emerging
infectious diseases and viruses, including Zika, Ebola,
West Nile and Chikungunya.
The gift will enable an ongoing, coordinated effort to
preserve blood and tissue from patients with various
diseases that display immune system involvement. With
patients’ permission, researchers will have access to blood
and tissue samples before, during and after treatment to
study a patient’s native immunity and how it might respond
to various therapeutic strategies. Such a resource could help
doctors understand the reasons a specific immune therapy is
effective in some patients but not others.
“Jane and I are both honored and humbled that we have
the opportunity to attach our names to the center, which we
believe has enormous potential for scientific discovery and
for improving the health, directly or indirectly, of the global
community,” Andrew Bursky said. “The speed at which the
center is translating ground-breaking discovery into new
modalities of personalized treatment is incredibly exciting.
We are very fortunate to be in a position to make a gift that
can have a meaningful impact
on the growth and impact of
the center.”

Alumni give back
Andrew Bursky is founder
and chief executive officer
of Atlas Holdings LLC, an
industrial holding company
based in Connecticut. Bursky
also serves as chairman of the
company, which employs more
than 23,000 people worldwide
and operates in a variety of
industries, including aluminum,
automotive, building materials,
construction, distribution,
energy, paper and packaging.
The Burskys have deep
connections to Washington
University, where Andrew
earned bachelor’s and master’s
Andrew M. and Jane M. Bursky
degrees in economics and
engineering and Jane earned a bachelor’s degree in French
and education. Andrew Bursky serves as a university trustee
and has received the School of Engineering’s Young Alumni
and Alumni Achievement Awards and the School of Arts &
Sciences Alumni Achievement Award. Together, they have
provided scholarships for students, including establishing the
Spirit of Washington University Scholarship.
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As they transition to the
next stage of their careers,
graduating students reflect
back on their medical journey.

Almost
Alumni
BY HILARY DAVIDSON

P

rior to Commencement, graduating students

in medicine, occupational therapy (OT) and
physical therapy (PT) took time out to reflect

on their graduate education and write notes of friendly
advice to incoming students.
Sponsored annually by the Office of Medical Alumni
and Development, these “Almost Alumni” luncheon
events give graduating students a chance to contemplate

Graduating students
dispense friendly advice to
entering medical classes

their new relationship with the medical school and
dispense a little hard-won wisdom.
Entering medical and physical therapy students
found the notecards tucked inside their new white coats,
presented during the white coat ceremonies in August.
Occupational therapy students will receive their handwritten messages in the fall.
Here, six students share their thoughts as they
transition to the next stage of their careers.
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Lawrence Benjamin

Tina Zhu

Salma Hussain

MD 16

MD 16

OTD 16

Benjamin is headed to Massachusetts
General Hospital for an internal medicine
residency. He advises new students to make
time for friends and for themselves. “There
will always be something you must study.
However, you will not always have time to
spend with friends. Prioritize your ‘me time,’
whether that is social or personal, and your
four years will be so much more enjoyable.”

Zhu is happy to be staying at Washington
University for her internal medicine residency.
“It’s exhilarating, seeing the results of my
hard work,” she said. “I’m ready to move on
to caring for my patients.” Zhu illustrated her
welcome message with playful drawings
of physicians holding stethoscopes, and
encouraged new students to “work hard and
stay focused, but make time to have fun.”

Weeks before Commencement, Hussain could
hardly believe that school was coming to an
end. “I feel like the time went by very quickly,”
she said. Hussain, who soon would begin
her occupational therapy fieldwork at the
Kennedy Krieger Institute in Baltimore,
welcomed new medical school students,
wishing them luck and “a wonderful first year.”

Max Lustick

Amanda Smith

Rachael Humber

MSOT 16

DPT 16

DPT 16

Although excited to soon be doing fieldwork
at a cancer rehabilitation institute in Salt Lake
City, Lustick said he would miss friends, mentors and colleagues at Washington University.
He advised: “Make as many connections as
you can while you are here. You’ll never be
around so many amazing people.”

Smith is returning to her native Indiana as
a pediatric physical therapist, and said
she would miss all the friends she found in
St. Louis. She described graduation as
“surreal.” “You make lifelong friends here,
and you’ll never all be in the same city
again, so it’s a good idea to spend time
together and make some memories.”

Humber’s next challenge: helping patients
with movement impairment due to neurological events such as traumatic brain injury,
spinal cord injury and stroke. “I get so excited
seeing the recovery of patients. This is exactly
what I wanted to do!” Humber told new students
to take full advantage of the opportunities
they have been given: “Enjoy your time here,
study hard, and have a great experience!”
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classnotes
1940 S
Robert Gibb, MD 48, received the
Dr. J. Richard Czajkowski Service Award
from Puget Sound Blood Center and is
president of the Western Pathologists
Quality Assurance Association.

1950 S
Lowell Gess, MD 51, an ophthalmologist,
recently returned from Sierra Leone, in
West Africa, where he worked with Ebola
responders and researchers on the virus’s
effects on eyesight. For 20 years, Gess and
his family lived in Sierra Leone, opening
an ophthalmology clinic, which is now
known as the Lowell and Ruth Gess UMC
Eye Hospital.
Max Heeb, MD 53, republished his
autobiography “Max the Knife: The Life
and Times of a Country Surgeon,” with
three additional chapters.
Albert Diddams, MD 56, has retired from
the U.S. Army and medical practice. He
enjoys gardening, golf and spending time
with his family.

Robert Froelich, MD 56, built and
solo-flew a Lancair IV 300 mph carbon
fiber aircraft. He enjoys flying and being
a member of the Experimental Aircraft
Association, United Flying Octogenarians
and Aircraft Owners & Pilots Association.

1960 S
Dale Heisinger, MD 66, is chairman of
the San Juan County (Washington) Board
of Health. He is also a proud husband,
father and grandfather.
Emily Smith, MD 68, stepped down at
the end of the 2015-16 fiscal year after 21
years of dedicated service as the School of
Medicine’s Annual Fund volunteer chair.

1970 S
Laura Wexler, MD 71, recently left
her position as senior associate dean
to concentrate on clinical care at the
Cincinnati Veterans Affairs Medical
Center and medical student teaching
at the University of Cincinnati College
of Medicine.

Alumni assume new posts

H

usband and wife Kevin A. Roth,
MD/PhD, HS ’89, and Robinna G.
Lorenz, MD/PhD ’90, HS, have made
numerous contributions to neuropathology, immunology and medical
education. With new positions, Roth
and Lorenz are broadening their spheres
of influence. In late 2015, Roth was
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named chair of the Department of
Pathology and Cell Biology at Columbia
University College of Physicians &
Surgeons and pathologist-in-chief
at New York-Presbyterian/Columbia
University Medical Center. Before going
to Columbia, Roth served as chair of
the Department of Pathology at the
University of Alabama at Birmingham
(UAB) School of Medicine.
In early 2016, Lorenz was promoted
to associate dean for physician scientist
development at UAB School of Medicine,
where she is also a professor of pathology
and directs the UAB Medical Scientist
Training Program and the Summer in
Biomedical Sciences Undergraduate
Research Program.

Linda Hershey, MD 76, has served as
director of the dementia program at the
University of Oklahoma Health Sciences
Center since 2010. She planned to retire
in June 2016.

1980 S
David “Dave” Baltzer, HA 81, has been
elected to a two-year term as president of
the 963-member Missouri chapter of the
American College of Healthcare Executives.

1990 S
Madeleine De Reding Kraus, MD 91,
moved to Orlando, Fla., to direct and
expand the section of hematology
and hematopathology at Nemours
Children’s Hospital.
Maral Kibarian Skelsey, MD 91, is
president of the Washington, D.C.,
Dermatologic Society and enjoys
volunteering on the board of The
Washington Ballet.

2000 S
Kathryn Lindley, HS 11, a cardiologist at
Washington University, has a keen interest
in heart disease in pregnant women. She
joined the faculty in mid-2014 and is working to establish a Women’s Heart Center,
which, she envisions, will encompass services from before pregnancy to end of life.

In Memory
A LU M N I
Virgil R. Bleisch, MD 48
Virgil R. Bleisch, a retired pathologist in
St. Louis, died Saturday, Feb. 13, 2016.
He was 92. Bleisch is remembered as a
physician, scholar, researcher, teacher,
soldier, mentor, adventurer, naturalist,
gardener, musician, conversationalist and
world traveler. He is survived by his wife,
Nadya; sister, Grace; children and their

Autumn 2016

Tape named American
College of Physicians Chair

T

homas G.
Tape, MD ’81,
FACP, has been
named chair of
the Board of
Regents of the American College of
Physicians (ACP). With more than
143,000 internist members, the ACP is
the largest medical specialty organization in the U.S. The Board of Regents
serves as its main policy-making body
and manages ACP business and affairs.
Tape also is division chief of general
internal medicine, vice chair for clinical
affairs in internal medicine and professor
of internal medicine at the University
spouses William and Yunhua, Barbara and
Dennis, Pamela and Timothy; grandchildren
Ivan, Misha, Nicholas, Emily, Reva and AK;
and nieces, nephews, great and great-great
nieces and nephews and cousins.
Jeffrey Peter Cichon, MD 79
Jeffrey Cichon, an orthopedic surgeon
in Las Vegas, died Wednesday, March
30, after a hard-fought battle with
pancreatic cancer. He was 62. Cichon
graduated summa cum laude from Saint
Louis University, completing a bachelor’s
degree in chemistry in just three years.
He earned a medical degree from WUSM
and later completed a residency at Los
Angeles County+University of Southern
California Medical Center. Cichon became
an associate professor at the University
of Nevada School of Medicine, as well as
an adjunct professor at Touro University.
He trained and mentored many students
who remember his commitment to treating patients not just with expert care, but
with respect and compassion. Cichon is
survived by his wife of 35 years, Vicki Lynn;
children Jamie, Danielle and Nickolas;
siblings John Cichon and Janelyn Wise;
and his mother, Helen Cichon.
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of Nebraska. His research focuses on
health policy, physician judgment and
decision making. As a member of a
medical center task force, he provides
health policy expertise to the
Nebraska region.
Tape has served the ACP in many
leadership capacities. His surveys of
ACP physician members have been
published in the Annals of Internal
Medicine and the American Journal of
Respiratory and Critical Care Medicine,
and he co-edited the ACP book
“Diagnostic Strategies for Common
Medical Problems.”

John Harsch, MD 83, HS 86
John Harsch, an internist in Henry County,
Ga., died Wednesday, April 6, 2016, when
he was struck by a car while cycling. He
was 59. Harsch received bachelor’s and
master’s degrees in physics from the
University of North Carolina-Chapel Hill
and a medical degree from WUSM. He went
on to co-found Southeastern Primary Care
Specialists. An avid soccer player, he transferred his passions to cycling and became
an active member of Southern Crescent
Cycling Club. Harsch is survived by his wife,
Mary Carol; mother, Cecilia Jean; siblings,
Donna Harsch and George Loewenstein,
Dr. Alan and Wendy Harsch, Cecily and Paul
Harsch-Kinnane, Douglas and Eden Harsch
and Dr. Richard and Jennifer Harsch; and
many nieces and nephews.
William Henry Martin, MD 58
William Henry Martin, a retired physician
in Red Bluff, Calif., died Tuesday, March
29, 2016. He grew up in hard times that
included living in an orphanage for two
years and developing an ear infection that
resulted in hearing loss in one ear. Martin
served in the military for four years after

high school and was recalled during the
Korean War. He would go on to complete
a bachelor’s degree in three years from
Arizona State University and a medical
degree at WUSM. Martin was active at
church and helped found the annual
Kiwanis summer camp serving disadvantaged youth. He is survived by his wife of
61 years, JoAnne, along with their four
children, Gary, Judy, Linda and Karen;
12 grandchildren; and brother David.
David Leon Rosenbaum, MD 60
David Rosenbaum died Wednesday, Dec.
23, 2015. He is survived by his wife, Sandra,
three children and six grandchildren.
Willard Daniel Rowland, MD 40
Willard Rowland, a pioneer in Oregon
plastic and reconstructive surgery, died
Tuesday, March 29, 2016, at his home in
Lake Oswego, Ore. He was 101. Rowland
completed undergraduate and medical
degrees at Washington University, became
a fellow at the Mayo Clinic in Rochester,
Minn., and then served in the burns and
reconstructive surgery division of the U.S.
Naval Hospital in Bethesda, Md., during
World War II. After the war, he helped
open the plastic surgery unit at the
Ochsner Clinic in New Orleans, La.,
developing new emphases in children’s
reconstruction. Rowland moved to
Portland, Ore., to establish one of the first
plastic surgery practices in the Pacific
Northwest, where his work focused
increasingly on children with congenital
deformities, burns and other traumas.
Later, he opened a second practice at
the Eisenhower Medical Center in Palm
Springs, Calif. He was predeceased by
his parents; brother, James; and wives,
Mary and Elynda. He is survived by his
children, Willard D. Rowland Jr. (Susan
Tannenbaum), Martha S. Rowland (Neil
Marquis), Charles Rowland (Cathy),
Anthony T. Rowland (Dolores) and Thomas
H. Rowland (Pat Harada); and 10 grandchildren and 10 great grandchildren.
Maxine Scheibe, NU 66
Maxine Scheibe died Thursday, June 18,
2015. Beloved wife of Robert Scheibe,
HS, MD 64, LA 60, and friend of and
scholarship donor to Washington
University School of Medicine.
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H. Richard Tyler, MD 51, HS
H. Richard Tyler, a Harvard emeritus
professor in neurology, died Sunday,
May 8, 2016. He was 88. After graduating
from Syracuse University in 1947, Tyler
volunteered for the U.S. Army and served
at the Los Alamos National Laboratory. He
earned an MD from WUSM and completed
a medical internship at the Peter Bent
Brigham Hospital, now known as Brigham
and Women’s, and a neurology residency
at Boston City Hospital. After completing
neurology fellowships at the Neurological
Institute at Queen Square in London, the
Salpetriere in Paris, and Johns Hopkins in
Baltimore, he returned to Boston to join
the faculty at Harvard Medical School,
where he became the first full-time neurologist at the Peter Bent Brigham Hospital
and led the neurology division from
1956-1988. He was appointed professor
of neurology at Harvard Medical School
in 1974 and became emeritus in 1999. His
renowned collection of rare medical books
was donated to the American Academy of
Neurology Book Collection at Washington
University. The 7,000-volume collection
includes many landmark books in neurology and neuroscience. He is survived by
his wife of 64 years, Joyce; four children,
Kenneth (Lisa), Karen, Douglas (Donna) and
Lori Spisak (Ken); grandchildren Maxwell,
Eric, Jason (Diane), Tanya (Matthew),
Nathan (Katie), Elaine, Britta, Colby,
Courtney, Hannah, Samantha, and Joe;
eight great grandchildren and nephews.

FAC U LT Y
Hugh Chaplin Jr., MD
Hugh Chaplin Jr., a hematologist, research
scientist and professor of medicine, died
Friday, April 29, 2016. He was 93. Chaplin
graduated from Princeton University
and the Columbia University College of
Physicians and Surgeons. While in college
and medical school, he served in the U.S.
Navy during the final months of World
War II. He performed his internal medicine residency at Massachusetts General
Hospital and became chief resident. He
entered an academic career through a
research fellowship in the U.S. Public
Health Service at the National Institutes of
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Health (NIH) and pursued additional training at the Medical Research Council Blood
Transfusion Research Unit in London. He
joined the WUSM faculty in 1955 and
held several leadership roles, including
as associate dean, director of the Irene
Walter Johnson Rehabilitation Institute
and director of the Barnes Hospital Blood
Bank. Chaplin authored more than 140
scientific articles and was recognized
internationally for his work on sickle cell
anemia, autoimmune hemolytic anemia,
transfusion reactions and blood banking.
In 2003, in honor of his longest-living
sickle cell patient and research colleague,
Chaplin self-published “Lenabell: A
Doctor’s Memoir of a Remarkable Woman’s
80-Year Battle With Sickle Cell Disease.”
In his retirement, Chaplin worked extensively for BJC Hospice in St. Louis, both
as a volunteer visitor with the dying and
as the organization’s pain management
consultant. Chaplin is survived by his
four children and their spouses, Kate and
Roger Woodward, David and Jane Chaplin,
Monique Chaplin and Mary McCartney,
and John Chaplin and Jill Adams; and
eight grandchildren and three great
grandchildren. Chaplin was preceded
in death by two beloved spouses, Alice
Dougherty Chaplin, after 52 years of
marriage, and Lee Nelken Robins, PhD,
with whom he enjoyed 11 years of marriage.
Mokhtar H. Gado, MD
Mokhtar H. Gado, for decades a leading
researcher at Mallinckrodt Institute of
Radiology (MIR) at WUSM, died Thursday,
April 28, 2016. He was 84. Gado, a professor emeritus of radiology, was noted for
his work with neurological diseases and
conducted extensive research involving
magnetic resonance imaging (MRI) of the
brain and spine. He was recognized for
his work regarding the radiological manifestations of Alzheimer’s disease and brain
changes in the elderly, and in the correlation of physical principles of magnetic
resonance to the pathologic changes
in the disease processes of the central
nervous system. Over the years, Gado
trained many of the nation’s top neuroradiologists. Gado was born in Monoufiah,
Egypt. He earned bachelor’s and medi-

cal degrees from Cairo University and
completed internships and residencies at
Cairo University Hospital, Addenbrooke’s
Hospital in Cambridge, England, and
what was then the National Hospital
for Nervous Diseases, in Queen Square,
London. He is survived by his longtime
wife, Sonja Gado; children, Karim, Yasmine,
Soraya and Ameer; brother, Kamel
Hishmat Gado; and two grandchildren.
Morvarid Karimi, MD
Morvarid Karimi, a tenacious researcher,
committed teacher and compassionate
clinician in the Department of Neurology,
died Saturday, May 21, 2016, of a brain
hemorrhage. She was 44. An assistant
professor in the department’s Movement
Disorders Section, Karimi also had a joint
appointment at Mallinckrodt Institute of
Radiology. As a physician, she specialized
in movement disorders, including dystonia
and Parkinson’s and Huntington’s diseases,
among other conditions, and conducted
research in Mallinckrodt’s Neuroimaging
Laboratories. In the lab, Karimi’s most
recent research focused on dystonia and
neuroimaging of dopamine pathways in
the brain. Karimi also was respected for
her attention to women’s rights, especially in the workplace. Born in Tehran,
Iran, Karimi earned a medical degree in
1999 from the University of Münster in
Germany. She moved to the U.S., where
she worked for a year at the Marshfield
Clinic in Marshfield, Wis. Karimi completed a neurology residency through the
University of Iowa in Iowa City, and landed
at WUSM for a three-year movement disorders fellowship. In 2007, she became an
instructor of neurology and, in 2010, an
assistant professor of neurology. Karimi
is survived by her husband, Eric Johnson,
MD, a hospitalist at Barnes-Jewish Hospital;
son, Kian; daughter, Suri; parents, Ebrahim
Karimi and Shahla Shahrokh; and brother,
Ali Karimi.
Marvin E. Levin, MD 51
Marvin Levin, a renowned endocrinologist
and teacher for many years at WUSM, died
Saturday, April 30, 2016. He was 91. Levin,
a professor emeritus of clinical medicine,
was an advocate for patients with diabetes.
He specialized in the treatment of the

Autumn 2016

diabetic foot and helped start WUSM’s foot
clinic. His goal was the prevention of lower
leg and foot amputations in people with
diabetes. He co-edited “The Diabetic Foot,”
currently titled “Levin and O’Neal’s: The
Diabetic Foot,” with Lawrence O’Neal, MD.
The classic textbook has been published in
several languages. Levin became professor
emeritus in 1995, but continued serving
the university through teaching and
committee service. He earned bachelor’s
and medical degrees from Washington
University. Levin then completed a
residency in medicine at Barnes Hospital
and an endocrinology and metabolism
fellowship at WUSM before joining the
clinical faculty in 1955. He is survived by
his wife of 40 years, Barbara; children,
Lynn, Judy and Michael; and three
grandchildren. His former wife, Gloria,
is deceased.
Philip W. Majerus, MD 61
Philip W. Majerus, a renowned hematologist
and professor emeritus of medicine at
WUSM, died Wednesday, June 8, 2016. He
was 79. Majerus is best known for research
showing that low-dose aspirin prevents
blood clots, reducing risk of heart attack
and stroke. The discovery is credited with
saving thousands of lives each year. Over a
career spanning more than four decades,
Majerus led research that describes the
way blood clots. His work studying aspirin
demonstrated that platelets play an active
role in clotting, overturning the long-held
idea that platelets were simply passive
components of blood clots. The work
on clotting led Majerus down additional
pathways, resulting in an extensive body
of work understanding the inositol system,
which is involved in blood clotting but
also has far-reaching roles in many other
cellular functions. Majerus joined the
WUSM faculty in 1966 as an assistant
professor of biochemistry and of medicine.
He became a professor of medicine in
1971 and a professor of biochemistry in
1976 and served on the medical school
faculty until 2014, when he was named
a professor emeritus of medicine. He
earned a bachelor’s degree in science in
1958 from Notre Dame University and his
medical degree in 1961 from Washington
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University. He completed his internship
and residency at Massachusetts General
Hospital and then served as a research
associate at what was then the National
Heart Institute. Majerus was a member
of the National Academy of Sciences,
the Institute of Medicine, the American
Academy of Arts and Sciences and the
American Society for Clinical Investigation.
He is survived by his wife, Elaine Majerus,
MD, PhD, an associate professor of medicine at WUSM; sisters Diane (Brick) Brewer
and Kathy (Roby) Burke; daughters,
Suzanne (Rodney) Thompson, Julie Del
Valle and Karen Majerus; son, David (Cecily)
Majerus; and four grandchildren.
Benjamin “Bud” Milder, MD 29
Benjamin Milder, a former faculty member
in ophthalmology, died Monday, May
16, 2016. Milder attended Washington
University as an undergraduate and
entered WUSM at age 19. He did an
ophthalmology residency at the University
of Chicago’s Billings Hospital, and worked
at Hines VA Hospital during World War II as
a major in the Army Medical Corps. After
the war, Milder joined the ophthalmology
faculty at WUSM and entered a private
practice. He authored or co-authored
numerous articles and medical texts,
including the award-winning “The Fine
Art of Prescribing Glasses Without Making
a Spectacle of Yourself.” Milder was a
frequent lecturer at medical conferences
around the globe. He is survived by his
wife, Jeanne Schieber; children, Michael
(Sarajane) Milder, MD 70, Barry (Shelly
Tobin) Milder, MD 73, Morton Milder, and
Rabbi Laurence (Janet Elis) Milder; grandchildren, Jonathan (Marlene), Daniel,
Kelly (Chad) Baldwin, Rabbi Rebecca
(Ethan Bueno de Mesquita), Rachel
(Adam) Lubchansky, Jacob (Julie, LA 03)
Milder, LA 03, Miriam, Avi, and Alex; and
10 great grandchildren.
Robert Charles Strunk, MD
Robert Strunk, a beloved and acclaimed
pediatric allergist at WUSM, died Thursday,
April 28, 2016. He was 73. For almost
three decades, Strunk, the Donald B.
Strominger Professor of Pediatrics, worked
in his lab, developing a productive
clinical and research program for

childhood asthma that significantly
enhanced the understanding of the
natural history of the disease and what
triggers it. During those years, Strunk
treated patients at St. Louis Children’s
Hospital, where he was the inaugural
director of the Division of Pediatric Allergy
and Pulmonary Medicine. His research
findings reflect the association between
emotional well-being and chronic asthma.
Additionally, Strunk’s research focused
on a long-term interest in fatal asthma,
including the disease’s role in children
with sickle cell disease. For decades,
Strunk followed children with asthma
into adulthood as part of the Childhood
Asthma Management Program, for which
he was a director. Strunk also had active
roles within the Pediatric Asthma Clinical
Research Network and the Childhood
Asthma Research and Education
Network. Strunk earned a bachelor’s
degree in chemistry, a medical degree
and a master’s in biochemistry, all from
Northwestern University. He completed
a pediatric internship and residency at
Cincinnati Children’s Hospital and then
was drafted into the military. During the
Vietnam War, he was a pediatrician at a
naval hospital in Newport, R.I. Afterward,
Strunk concurrently completed two
fellowships in 1974, at Harvard Medical
School and Boston Children’s Hospital.
Besides clinical research and treating
patients, Strunk proved pivotal in enlisting
the National Institutes of Health (NIH)
to support several national pediatric
asthma initiatives. Improving the health
of asthmatic children in economically
disadvantaged neighborhoods was deeply
important to him. Strunk was instrumental
in establishing the Healthy Kids Express,
a fully equipped and staffed mobile clinic
that provides asthma care for children in
underserved communities in Missouri. He
is survived by his wife of 18 years, Juanita
Strunk; two children, Chris Strunk and Alix
Strunk; two stepchildren, Rick Macivor and
Ellen Royal; and nine grandchildren.
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Advancing Health,
Transforming Lives
Great news! The law allowing tax-free charitable IRA gifts is now permanent.
If you are age 70½ or older, you can reduce your taxable income by making tax-free
gifts up to $100,000 each calendar year directly from your IRA to Washington
University School of Medicine. Best of all, your gift will be used as you wish to
support scholarships, professorships, research or another purpose you choose!

Make a tax-free charitable IRA
gift by year-end and:
n
n
n

Reduce your taxable income
Satisfy your required minimum distribution
Support the School of Medicine

To qualify:
n

n

n

To learn more or notify us of your gift,
contact the Office of Planned Giving at
800-835-3503 or plannedgiving@wustl.edu.
Consult with your legal or tax adviser before making a charitable gift.

You must be 70½ years of age or older when
the distribution is made.
The transfer must go directly from your IRA to
Washington University.
Your gift must be outright. Tax-free charitable IRA
gifts cannot be used to fund a gift annuity, charitable
trust, donor-advised fund or private foundation.

TIM PARKER

Key moment
John Harley, MD ’66, vividly recalls the “topping out” of the
Gateway Arch on Oct. 28, 1965. Harley, then a fourth-year
medical student, had heard that the 10-ton keystone —
the final piece of the Arch — would be hoisted into place
that day. He and several classmates looked for a high place
on campus to watch the action. Queeny Tower was under
construction, and the young men found an unattended
service elevator. “We got out on the roof,” Harley said.
“We could see the Arch with two giant cranes next to it.
The cranes came in and put in the last piece.” Harley
graduated in 1966, and chose radiology as his specialty.
He settled down in the Pacific Northwest, but he never
forgot that moment. “We knew that we were witnessing
a piece of history,” he said. Harley returned to the School
of Medicine this May to celebrate his 50th Reunion. While
here, he visited the Arch, which turned 50 in October 2015.
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Alumni advice
This past spring, soon-to-be graduates
took time to reflect and write some
notes of friendly advice. Entering
students found the notecards tucked
inside the pockets of their new white
coats, which they received during the
White Coat ceremonies in August.
See story, page 34.
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